Is the GSK share price a FTSE 100 bargain? Here’s what the charts say!
The stable nature of medicine demand makes pharmaceutical companies popular with investors during uncertain times. But FTSE 100-listed GSK‘s (LSE:GSK) share price has dropped 4% since 1 January as share pickers have invested elsewhere.
The healthcare giant has its problems. But at a current price of £13.78 per share it does, on paper at least, offer great value when compared to other UK blue-chip shares.
GSK trades on a forward price-to-earnings (P/E) ratio of 9.3 times, below the FTSE average of 14 times. Furthermore, its 4% dividend yield beats the index’s 3.7% average.
It’s worth remembering that the FTSE index is hugely diverse, though. So comparing the company with other major players in its industry rather than just its index is a useful exercise.
How does GSK’s share price stack up on this front?
P/E ratio
A good starting point is to consider how the company is priced in relation to predicted future earnings. This can be calculated using the P/E ratio for the current financial year.
On this front GSK makes a strong impression. Its multiple is less than half that of FTSE 100 rival AstraZeneca‘s 18.6 times.
The UK business also looks cheap compared to its international peers. Pfizer trades on a P/E ratio of 11.2 times for 2023, while Merck & Co and Eli Lilly carry enormous multiples of 35.4 times and 56.2 times, respectively.
P/CF ratio
The value of GSK’s shares isn’t as clear cut on a price-to-cash flow (P/CF) basis isn’t as clear cut, though, as the chart above shows. This is a useful metric to use for businesses that require vast amounts of capital like pharmaceuticals firms.
Aside from Eli Lilly, which trades on a monster reading above 80, it sits fairly close to its sector peers. That said, it is only beaten by Pfizer on this metric.
Dividend yield
Drugs developers aren’t famed for paying especially large dividends. This is on account of their colossal research and development costs. Last year GSK announced it would spend £1bn over the next decade to produce vaccines and treatments for malaria, tuberculosis, HIV, neglected tropical diseases, and antimicrobial resistance alone.
Yet the business still offers that large 4% dividend yield, as I mentioned. And as the chart shows, this is far above what its industry peers (bar Pfizer) currently offer.
Why I’d buy today
Concerns over the size of the firm’s pipeline is the main reason GSK trades more cheaply than its rivals. However, I feel this problem could be baked into the current price of its shares, and especially when considering the stock’s P/E ratio.
It’s my belief that its share price could rise strongly over the long term. Revenues from products launched since 2017 have been impressive, while margins are improving, leading to upgrades to sales and profit forecasts.
GSK has a great track record of creating industry-leading treatments. Indeed, its money-spinning Shingrix shingles vaccine has just shown 100% efficacy during trials in China. And as global demand for medicines marches higher, I expect the FTSE business to generate excellent shareholder returns.
The post Is the GSK share price a FTSE 100 bargain? Here’s what the charts say! appeared first on The Motley Fool UK.
5 Shares for the Future of Energy
Investors who don’t own energy shares need to see this now.
Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.
While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions,
he says. Mark believes 5 companies in particular are poised for spectacular profits.
Open this new report — 5 Shares for the Future of Energy
— and discover:
- Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
- How to potentially get paid by the weather
- Electric Vehicles’ secret
backdoor
opportunity - One dead simple stock for the new nuclear boom
Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!
Grab your FREE Energy recommendation now
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#FFFFFF”, ‘color’, ‘#FFFFFF’);
})()
More reading
- BP shares are tempting, but I’d buy these FTSE 100 stocks instead
- With a dividend of 8.1%, are Taylor Wimpey shares a buy?
- Here are 5 LSE dividend stocks with yields over 8%
- Is it worth buying the likely 4 promoted FTSE 100 shares?
- Here are 2 of my best stocks to buy for passive income
Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
